These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15213099)

  • 1. Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice.
    Pelletier SD; Hong DS; Hu Y; Liu Y; Li S
    Blood; 2004 Oct; 104(7):2163-71. PubMed ID: 15213099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia.
    Jiang X; Stuible M; Chalandon Y; Li A; Chan WY; Eisterer W; Krystal G; Eaves A; Eaves C
    Blood; 2003 Oct; 102(8):2976-84. PubMed ID: 12829595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.
    Krause DS; Lazarides K; von Andrian UH; Van Etten RA
    Nat Med; 2006 Oct; 12(10):1175-80. PubMed ID: 16998483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche.
    Krause DS; Lazarides K; Lewis JB; von Andrian UH; Van Etten RA
    Blood; 2014 Feb; 123(9):1361-71. PubMed ID: 24394666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
    Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
    Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
    Gustafsson K; Jamalpour M; Trinh C; Kharas MG; Welsh M
    J Hematol Oncol; 2014 Jun; 7():45. PubMed ID: 24952416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
    Hao SX; Ren R
    Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.
    Mumprecht S; Claus C; Schürch C; Pavelic V; Matter MS; Ochsenbein AF
    Blood; 2009 May; 113(19):4681-9. PubMed ID: 19252140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
    Peng C; Li S
    Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
    Gross AW; Zhang X; Ren R
    Mol Cell Biol; 1999 Oct; 19(10):6918-28. PubMed ID: 10490629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
    Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
    Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
    Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
    Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
    Zhang X; Wong R; Hao SX; Pear WS; Ren R
    Blood; 2001 Jan; 97(1):277-87. PubMed ID: 11133772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.